Effect of tubeimoside I on the activity of cytochrome P450 enzymes in human liver microsomes

References

• Achour B, Barber J, Rostami-Hodjegan A. 2014. Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos. 42(8):1349–1356. doi: 10.1124/dmd.114.058834.
   PubMed Web of Science ®Google Scholar
• Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. 2018. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 84(12):2704–2715. doi: 10.1111/bcp.13741.
   PubMed Web of Science ®Google Scholar
• Berry LM, Zhao Z, Lin MH. 2013. Dynamic modeling of cytochrome P450 inhibition in vitro: impact of inhibitor depletion on IC50 shift. Drug Metab Dispos. 41(7):1433–1441. doi: 10.1124/dmd.113.051508.
   PubMed Web of Science ®Google Scholar
• Cheng G, Zhang Y, Zhang X, Tang HF, Cao WD, Gao DK, Wang XL. 2006. Tubeimoside V (1), a new cyclic bisdesmoside from tubers of Bolbostemma paniculatum, functions by inducing apoptosis in human glioblastoma U87MG cells. Bioorg Med Chem Lett. 16(17):4575–4580. doi: 10.1016/j.bmcl.2006.06.020.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Lv D, Luo M, Wang R, Guo Y, Yang X, Huang L, Li X, Li C, Shang FF, et al. 2021. Tubeimoside I protects against sepsis-induced cardiac dysfunction via SIRT3. Eur J Pharmacol. 905:174186. doi: 10.1016/j.ejphar.2021.174186.
   PubMed Web of Science ®Google Scholar
• Gougis P, Hilmi M, Geraud A, Mir O, Funck-Brentano C. 2021. Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments. Crit Rev Oncol Hematol. 166:103342. doi: 10.1016/j.critrevonc.2021.103342.
   PubMed Web of Science ®Google Scholar
• Han M, Zhang X, Ye Z, Wang J, Kong Q, Hu X, Qian J, Cai J, Hu G. 2022. Effects of CYP2D6 genetic polymorphism and drug interaction on the metabolism of dacomitinib. Chem Res Toxicol. 35(2):265–274. doi: 10.1021/acs.chemrestox.1c00327.
   PubMed Web of Science ®Google Scholar
• Haupt LJ, Kazmi F, Ogilvie BW, Buckley DB, Smith BD, Leatherman S, Paris B, Parkinson O, Parkinson A. 2015. The reliability of estimating Ki values for direct, reversible inhibition of cytochrome P450 enzymes from corresponding IC50 values: a retrospective analysis of 343 experiments. Drug Metab Dispos. 43(11):1744–1750. doi: 10.1124/dmd.115.066597.
   PubMed Web of Science ®Google Scholar
• Hu X, Ni J, Gao N, Ye Z, Hu G, Cai J, Qian J. 2022. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline. Chem Biol Interact. 366:110123. doi: 10.1016/j.cbi.2022.110123.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, Wang K, Chen D. 2017. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica. 47(10):849–855. doi: 10.1080/00498254.2016.1257171.
   PubMed Web of Science ®Google Scholar
• Lin L, Wang Y, Shao S, Lin W, Huang D, Dai Y, Xia Y. 2022. Herb-drug interaction between Shaoyao-Gancao-Fuzi decoction and tofacitinib via CYP450 enzymes. J Ethnopharmacol. 295:115437. doi: 10.1016/j.jep.2022.115437.
   PubMed Web of Science ®Google Scholar
• Lv D, Luo M, Cheng Z, Wang R, Yang X, Guo Y, Huang L, Li X, Huang B, Shen J, et al. 2021. Tubeimoside I ameliorates myocardial ischemia-reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis. Oxid Med Cell Longev. 2021:1–22. doi: 10.1155/2021/5577019.
   Web of Science ®Google Scholar
• Machalz D, Pach S, Bermudez M, Bureik M, Wolber G. 2021. Structural insights into understudied human cytochrome P450 enzymes. Drug Discov Today. 26(10):2456–2464. doi: 10.1016/j.drudis.2021.06.006.
   PubMed Web of Science ®Google Scholar
• Patel G, Thakur NS, Kushwah V, Patil MD, Nile SH, Jain S, Kai G, Banerjee UC. 2020. Mycophenolate co-administration with quercetin via lipid-polymer hybrid nanoparticles for enhanced breast cancer management. Nanomedicine. 24:102147. doi: 10.1016/j.nano.2019.102147.
   PubMed Web of Science ®Google Scholar
• Pingili R, Vemulapalli S, Mullapudi SS, Nuthakki S, Pendyala S, Kilaru N. 2016. Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in Wistar rats. Drug Dev Ind Pharm. 42(7):1110–1117. doi: 10.3109/03639045.2015.1115868.
   PubMed Web of Science ®Google Scholar
• Ring B, Wrighton SA, Mohutsky M. 2021. Reversible mechanisms of enzyme inhibition and resulting clinical significance. Methods Mol Biol. 2342:29–50. doi: 10.1007/978-1-0716-1554-6_2.
   PubMedGoogle Scholar
• Ruan C, You L, Qiu Y, Cui X, Wu D. 2020. Tubeimoside I induces autophagy in HepG2 cells by activating the AMP-activated protein kinase signaling pathway. Oncol Lett. 20(1):623–630. doi: 10.3892/ol.2020.11604.
   PubMed Web of Science ®Google Scholar
• Sun Y, He M, Sun Y, Wei J. 2021. 4-O-galloylalbiflorin inhibits the activity of CYP3A, 2C9, and 2D in human liver microsomes. Xenobiotica. 51(8):871–876. doi: 10.1080/00498254.2021.1936688.
   PubMed Web of Science ®Google Scholar
• Tang Q, Cao H, Tong N, Liu Y, Wang W, Zou Y, Xu L, Zeng Z, Xu W, Yin Z, et al. 2022. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 99:154016. doi: 10.1016/j.phymed.2022.154016.
   PubMed Web of Science ®Google Scholar
• Tornio A, Backman JT. 2018. Cytochrome P450 in pharmacogenetics: an update. Adv Pharmacol. 83:3–32. doi: 10.1016/bs.apha.2018.04.007.
   PubMedGoogle Scholar
• van der Lee M, Guchelaar HJ, Swen JJ. 2021. Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics. 22(16):1081–1089. doi: 10.2217/pgs-2021-0093.
   PubMed Web of Science ®Google Scholar
• Vanhove T, Annaert P, Knops N, de Loor H, de Hoon J, Kuypers DRJ. 2019. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. Basic Clin Pharmacol Toxicol. 124(1):50–55. doi: 10.1111/bcpt.13092.
   PubMed Web of Science ®Google Scholar
• Wang CL, Gao MZ, Gao DM, Guo YH, Gao Z, Gao XJ, Wang JQ, Qiao MQ. 2022. Tubeimoside-1: a review of its antitumor effects, pharmacokinetics, toxicity, and targeting preparations. Front Pharmacol. 13:941270. doi: 10.3389/fphar.2022.941270.
   PubMed Web of Science ®Google Scholar
• Wang J, Mei QX. 2021. Literature research of Compendium of Materia Medica quoted from Bencao Tujing. Zhonghua Yi Shi Za Zhi. 51:34–42.
   PubMedGoogle Scholar
• Wang K, Zhan Y, Chen B, Lu Y, Yin T, Zhou S, Zhang W, Liu X, Du B, Wei X, et al. 2020. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 11(8):708. doi: 10.1038/s41419-020-02915-x.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang X, Wang Z, Lv X, Yin H, Li W, Li W, Jiang L, Liu Y. 2022. Potential herb-drug interaction risk of thymoquinone and phenytoin. Chem Biol Interact. 353:109801. doi: 10.1016/j.cbi.2022.109801.
   PubMed Web of Science ®Google Scholar
• Waring RH. 2020. Cytochrome P450: genotype to phenotype. Xenobiotica. 50(1):9–18. doi: 10.1080/00498254.2019.1648911.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ya G, Rui H. 2017. Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. Eur J Drug Metab Pharmacokinet. 42(1):89–98. doi: 10.1007/s13318-016-0323-8.
   PubMed Web of Science ®Google Scholar
• Zhang ZB, Zheng JS. 2019. Study on the misprints of the primary version of the Compendium of Materia Medica. Zhonghua Yi Shi Za Zhi. 49:146–162.
   PubMedGoogle Scholar
• Zhao P. 2008. The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol. 4(2):151–164. doi: 10.1517/17425255.4.2.151.
   PubMed Web of Science ®Google Scholar
• Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 9(4):310–322. doi: 10.2174/138920008784220664.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu J, Zhang J, Xu Y, Li W, Gao P, Xing Y, Huang L, Qin X, Jin S. 2022. Chinese endemic medicinal plant Bolbostemma paniculatum (Maxim.) Franquet: a comprehensive review. Front Pharmacol. 13:974054. doi: 10.3389/fphar.2022.974054.
   PubMed Web of Science ®Google Scholar